Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 32Completed 12Recruiting 5Not yet recruiting 3Active not recruiting 3Withdrawn 1Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13sintilimab 12Drug Therapy 12Docetaxel 12tislelizumab 11Trastuzumab 10Cisplatin 10Irinotecan 8Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7fludarabine 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Cyclophosphamide 7Biopsy 7disitamab vedotin 6Hyperthermic Intraperitoneal Chemotherapy 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × apatinib × Clear all
NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
550 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07311408 2025-12-31

SHR-2554

China Medical University, China

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

Peking University Third Hospital

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06485271 2024-07-03

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Changzhi People's Hospital Affiliated to Changzhi Medical College

Recruiting
504 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06415669 2024-05-29

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡